June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Breast Show-Me-Tips
Coding...Abstracting...Education… Coding Systemic Therapy
Breast Cancer Systemic Therapy
Chemotherapy Subcategory
Abraxane (Protein-bound Paclitaxel) Taxane
Afinitor (Everolimus) Cytostatic agent-antiangiogenesis agent and mTOR inhibitor
Capecitabine (Xeloda) Antimetabolite
Carboplatin (Paraplatin) Alkylating agent, Platinum analog
Cyclophosphamide (Cytoxan, Clafen) Alkylating agent
Docetaxel (Taxotere) Taxane
Doxorubicin (Adriamycin) Antitumor antibiotic
Epirubicin (Epirubicin Hydrochloride, Ellence) Anthracycline, Antitumor antibiotic
Epothilone (Ixabepilone, Ixempra) Antimitotic agent
Eribulin (Eribulin mesylate, Halaven) Inhibitor of microtubular dynamics
Fluorouracil (5-FU) Antimetabolite Gemcitabine (Gemzar, Gemcitabine Hydrochloride) Antimetabolite
Lapatinib Ditosylate (Tykerb) Tyrosine kinase inhibitor
Methotrexate (Folex, Folex PFS, Mexate, Mexate AQ) Antimetabolite
Paclitaxel (Taxol) Mitotic inhibitor, plant alkaloid, Taxane
Palbociclib (Ibrance) CDK inhibitor
Thiotepa (Thioplex) Alkylating agent
Vinblastine (Velban, Velsar, Vinblastine Sulfate) Plant alkaloid
Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR
This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 1
June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Breast Show-Me-Tips
Coding...Abstracting...Education… Coding Systemic Therapy Breast Cancer Systemic Therapy
Hormone Therapy Subcategory Anastrozole (Arimidex) Aromatase inhibitor Exemestane (Aromasin) Aromatase inhibitor Fulvestrant (Faslodex) SERD Goserelin Acetate (Zoladex) Gonadotropin-releasing hormone Letrozole (Femara) Nonsteroidal aromatase inhibitor Megesterol Acetate (Megace) Progestin Tamoxifen (Nolvadex, Tamoxifen Citrate) Nonsteroidal antiestrogen
Biological Response Modifiers Subcategory
Ado-trastuzumab emtansine (Kadcyla) Antibody-drug conjugate Pertuzumab (Perjeta) Cytostatic agent—tyrosine kinase inhibitor Humanized monoclonal antibody
Trastuzumab (Herceptin) Targeted therapy—epidermal growth factor receptor
Common Regimens Biophosphates (NOT CODED) AC: Adriamycin & Cytoxan (Ancillary Agents given for Bone Mets) AC-T: Adriamycin, Cytoxan then Taxol CAF: Cytoxan, Adriamycin & 5-FU Denosumab (Xgeva) coded if given to treat Giant CMF: Cytoxan, Methotrexate & 5-FU Cell Tumors of the Bone FEC: 5-FU, Epirubicin & Cytoxan Pamidronate Disodium (Aredia) TAC: Taxotere, Adriamycin & Cytoxan Zoledronic acid (Zometa) TCH: Taxotere, Carboplatin & Herceptin TC: Taxotere & Cytoxan
Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR
This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 2